Hashimoto’s Thyroiditis is Not a Negative Contributor to Papillary Thyroid Cancer

Zeynep Çetin; Özden Başer; Serdar Güler

doi:10.54614/eurjther.2022.0052

Authors

Zeynep Çetin Department of Endocrinology and Metabolism, Amasya University, Sabuncuoglu Serefeddin Education and Research Hospital, Amasya, Turkey
Özden Başer Department of Endocrinology and Metabolism, Yozgat City Hospital, Yozgat, Turkey
Serdar Güler Department of Endocrinology and Metabolism, Ankara Liv Hospital, Ankara, Turkey

DOI:

https://doi.org/10.54614/eurjther.2022.0052

Keywords:

Hashimoto’s thyroiditis, risk, papillary

Abstract

Objective: Hashimoto’s thyroiditis is the most common autoimmune thyroid disease. Papillary thyroid cancer is the most common thyroid cancer. Whether Hashimoto’s thyroiditis is a predisposing factor for papillary thyroid cancer remains unclear. In this study, the frequency of papillary thyroid cancer was investigated in patients with Hashimoto’s thyroiditis who underwent total thyroidectomy.

Methods: In this study, 534 patients were screened retrospectively. Preoperative thyroid function tests, anti-thyroid antibodies, ultrasonography findings, fine-needle aspiration biopsies, and thyroidectomy pathology results were examined. According to the pathology, 139 patients had Hashimoto’s thyroiditis. Patients with Hashimoto’s thyroiditis (group 1) and non-Hashimoto’s thyroiditis (group 2) were compared.

Results: Papillary thyroid cancer was found in 70 patients (50.4%) in group 1 and 156 patients (39.5%) in group 2 (P=.026). The odds ratio was 1.59 (95% CI; 1.07-2.34). There was no difference for sex, age, tumor size, microcarcinoma–macrocarcinoma distribution, subtype, number of tumor focus, lymph node metastasis, vessel invasion, and extrathyroidal spread.

Conclusion: We found more papillary thyroid cancer and less capsular invasion in patients with Hashimoto’s thyroiditis, but we did not find any differences between groups in terms of age, gender, tumor size, vascular invasion, and metastasis. According to these findings, Hashimoto’s thyroiditis may be a risk factor for papillary thyroid cancer.

Metrics

Metrics Loading ...

References

Jankovic B, Le KT, Hershman JM. Clinical Review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab. 2013;98(2):474-482.

Ozmen S, Yılmaz HT, Çalik I, et al. Histopathological results of suspicious nodules in the patients with Hashimoto thyroiditis. BSJ Health Sci. 2020;3(1):8-11.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.

Baser H, Ozdemir D, Cuhaci N, et al. Hashimoto’s thyroiditis does not affect ultrasonographical, cytological and histopathological feautres in patients with papillary thyroid carcinoma. Endocr Pathol. 2015;26(4):356-364.

Girardi FM, Barra MB, Zettler CG. Papillary thyroid carcinoma: does the association with Hashimoto’s thyroiditis affect the clinicopathological characteristics of the disease? Braz J Otorhinolaryngol. 2015;81(3):283-287.

Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria and Explanatory Notes. New York: Springer; 2010.

Uhliarova B, Hajtman A. Hashimoto’s thyroiditis - an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol. 2018;84(6):729-735.

Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-397.

Mazokopakis EE, Tzortzinis AA, Dalieraki-Ott EI, et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. A retrospective study. Hormones (Athens). 2010;9(4):312-317.

Mazokopakis EE, Kotsiris DA. Hashimoto's autoimmune thyroiditis and vitamin D deciency. Current aspects. Hell J Nucl Med. 2014;17(1):37-40.

Anderson L, Middleton WD, Teefey SA, et al. Hashimoto thyroiditis: Part 2, sonographic analysis of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis. AJR Am J Roentgenol. 2010;195(1):216-222.

Azizi G, Keller JM, Lewis M, et al. Association of Hashimoto’s thyroiditis with thyroid cancer. Endocr Relat Cancer. 2014;21(6):845-852.

Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011;96(12):3615-3627.

Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in ultrasound consensus conference statement. Radiology. 2005;237(3):794-800.

Takashima S, Matsuzuka F, Nagareda T, Tomiyama N, Kozuka T. Thyroid nodules associated with Hashimoto’s thyroiditis: assessment with. Radiology. 1992;185(1):125-130.

Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpabl thyroid nodules: predictive value of ultrasound and colorDoppler features. J Clin Endocrinol Metab. 2002;87(5):1941-1946.

Ceratti S, Giannini P, Souza RAdSe, Rodrigues Junior OF. Ultrasoundguided fine-needle aspiration of thyroid nodules: assessment of the ideal number of punctures. Radiol Bras. 2012;45(3):145-148.

Baskin J, Duick D, Guttler R. Position paper on FNA for non-palpabl thyroid nodules 2009 Academy of Clinical Thyroidologists web site. Available at:

Efremidou EI, Papageorgiou MS, Liratzopoulos N, Manolas KJ. The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can J Surg. 2009;52(1):39-44.

Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary thyroid cancer and Hashimoto’s thyroiditis: an association less understood. Indian J Surg Oncol. 2014;5(3):199-204.

Konturek A, Barczyński M, Nowak W, Wierzchowski W. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto's thyroiditis. Langenbecks Arch Surg. 2014;399(2):229-236.

Babli S, Payne RJ, Mitmaker E, Rivera J. Effects of chronic lymphocytic thyroiditis on the clinicopathological features of papillary thyroid cancer. Eur Thyroid J. 2018;7(2):95-101.

Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71(10):874-878.

Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150(1):49-52.

McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012;97(8):2682-2692.

Ahn D, Heo SJ, Park JH, et al. Clinical relationship between Hashimoto’s thyroiditis and papillary thyroid cancer. Acta Oncol. 2011;50(8):1228-1234.

Borowczyk M, Janicki A, Dworacki G, et al. Decreased staging of differentiated thyroid cancer in patients with chronic lymphocytic thyroiditis. J Endocrinol Invest. 2019;42(1):45-52.

Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71(4):581-586.

Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19(2):137-141.